BIGBEAR
PHARMACEUTICAL
Encorafenib is an oral, highly selective BRAF V600 mutant kinase inhibitor, often used in combination with MEK inhibitors for enhanced efficacy.
AuthenticGuaranteeFast DeliveryPrivacy Approval Details and BackgroundArray BioPharma Announces FDA Approval of Braftovi (encorafenib) in Combination with Mektovi (binimetinib) for Unresect···【More】
Update: 25 Feb,2026Source: BigbearViews: 109
Approval Details and BackgroundApril 8, 2020 - Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved B···【More】
Update: 25 Feb,2026Source: BigbearViews: 105
Approval Details and BackgroundNEW YORK--(BUSINESS WIRE) October 12, 2023 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Admin···【More】
Update: 25 Feb,2026Source: BigbearViews: 108
Approval Details and BackgroundNEW YORK--(BUSINESS WIRE) December 20, 2024 -- Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Admi···【More】
Update: 25 Feb,2026Source: BigbearViews: 108
Study Publication and BackgroundFRIDAY, May 30, 2025 -- For patients with BRAF V600E-mutated metastatic colorectal cancer, progression-free and overal···【More】
Update: 25 Feb,2026Source: BigbearViews: 108
Approval AnnouncementNEW YORK—(BUSINESS WIRE) February 24, 2026 — Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (···【More】
Update: 25 Feb,2026Source: BigbearViews: 115
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
